Similar articles

• Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection?

  Papatheodoridis GV, Manesis EK, Manolakopoulos S, Elefsiniotis IS, Goulis J, Giannousis J, Bilalis A, Kafiri G, Tzourmakliotis D, Archimandritis AJ. Papatheodoridis GV, et al. Hepatology. 2008 Nov;48(5):1451-9. doi: 10.1002/hep.22518. Hepatology. 2008. PMID: 18924246
• Changing landscape of antiviral resistance management in chronic hepatitis B.

  Nguyen T, Locarnini S, Desmond P. Nguyen T, et al. J Gastroenterol Hepatol. 2008 Sep;23(9):1314-7. doi: 10.1111/j.1440-1746.2008.05551.x. J Gastroenterol Hepatol. 2008. PMID: 18853991 No abstract available.
• A call for attention and trials on hepatitis B e antigen-negative, alanine aminotransferase-normal chronic hepatitis B virus infection.

  Zhao H, Miao R. Zhao H, et al. Hepatology. 2009 Aug;50(2):658; author reply 658-9. doi: 10.1002/hep.23110. Hepatology. 2009. PMID: 19585650 No abstract available.
• [Entecavir: a new hope for the treatment of chronic hepatitis B].

  Calleja JL, Peñas B. Calleja JL, et al. Gastroenterol Hepatol. 2007 May;30(5):285-93. doi: 10.1157/13101981. Gastroenterol Hepatol. 2007. PMID: 17493440 Review. Spanish. No abstract available.
• Hepatitis B: the pathway to recovery through treatment.

  Hollinger FB, Lau DT. Hollinger FB, et al. Gastroenterol Clin North Am. 2006 Dec;35(4):895-931. doi: 10.1016/j.gtc.2006.10.002. Gastroenterol Clin North Am. 2006. PMID: 17129820 Review. No abstract available.